AR122711A1 - COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA - Google Patents
COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINAInfo
- Publication number
- AR122711A1 AR122711A1 ARP210101721A ARP210101721A AR122711A1 AR 122711 A1 AR122711 A1 AR 122711A1 AR P210101721 A ARP210101721 A AR P210101721A AR P210101721 A ARP210101721 A AR P210101721A AR 122711 A1 AR122711 A1 AR 122711A1
- Authority
- AR
- Argentina
- Prior art keywords
- kinase
- inhibitor
- heterocyclic compound
- receptor type
- activin receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto representado por la siguiente fórmula (1) caracterizado porque R¹ a R¹⁰ cada uno de modo independiente representa hidrógeno, alquilo, cicloalquilo, o un halógeno, en donde R² y R³ o R⁴ y R⁵ juntos con dos átomos de carbono a los que están unidos forman un anillo de 5 miembros que contiene un heteroátomo seleccionado del grupo que consiste en un átomo de oxígeno, un átomo de nitrógeno, y un átomo de azufre, opcionalmente sustituido con alquilo; o una de sus sales farmacéuticamente aceptables, en donde el compuesto excluye 2-[4-(2,3-dihidro-5-benzofuranil)-2-(1,1-dimetiletil)-1H-imidazol-5-il]-6-metilpiridina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020109452 | 2020-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122711A1 true AR122711A1 (es) | 2022-09-28 |
Family
ID=79281234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101721A AR122711A1 (es) | 2020-06-25 | 2021-06-23 | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230183220A1 (es) |
| EP (1) | EP4174061A4 (es) |
| JP (1) | JP7398159B2 (es) |
| KR (1) | KR20230025007A (es) |
| CN (1) | CN116034105A (es) |
| AR (1) | AR122711A1 (es) |
| AU (1) | AU2021296087B2 (es) |
| BR (1) | BR112022026403A2 (es) |
| CA (1) | CA3182966A1 (es) |
| IL (1) | IL298559A (es) |
| MX (1) | MX2022014760A (es) |
| TW (1) | TW202216695A (es) |
| WO (1) | WO2021261544A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001178508A (ja) | 1999-12-27 | 2001-07-03 | Ykk Corp | スライドファスナー用ファスナーエレメント |
| AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| JP2004517068A (ja) * | 2000-11-16 | 2004-06-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| DE60226756D1 (de) | 2001-10-04 | 2008-07-03 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| WO2008071605A2 (en) | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| ES2460065T3 (es) * | 2009-10-28 | 2014-05-13 | Pfizer Inc. | Derivados de imidazol como inhibidores de la caseína quinasa |
| ES2650744T3 (es) * | 2010-12-14 | 2018-01-22 | Electrophoretics Limited | Inhibidores de la caseína quinasa 1 delta (CK1delta) |
| EP3064222B1 (en) | 2013-10-31 | 2020-10-21 | Kyoto Prefectural Public University Corporation | Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| KR20150064768A (ko) | 2013-12-03 | 2015-06-12 | 노승철 | 상품정보 등록 시스템 및 그 방법 |
| US10722513B2 (en) * | 2015-03-23 | 2020-07-28 | The University Of Melbourne | Treatment of respiratory diseases |
-
2021
- 2021-06-23 AR ARP210101721A patent/AR122711A1/es unknown
- 2021-06-24 CA CA3182966A patent/CA3182966A1/en active Pending
- 2021-06-24 MX MX2022014760A patent/MX2022014760A/es unknown
- 2021-06-24 US US17/925,904 patent/US20230183220A1/en active Pending
- 2021-06-24 TW TW110123102A patent/TW202216695A/zh unknown
- 2021-06-24 AU AU2021296087A patent/AU2021296087B2/en active Active
- 2021-06-24 JP JP2022532529A patent/JP7398159B2/ja active Active
- 2021-06-24 EP EP21827568.3A patent/EP4174061A4/en active Pending
- 2021-06-24 BR BR112022026403A patent/BR112022026403A2/pt unknown
- 2021-06-24 IL IL298559A patent/IL298559A/en unknown
- 2021-06-24 CN CN202180044861.8A patent/CN116034105A/zh active Pending
- 2021-06-24 KR KR1020237001830A patent/KR20230025007A/ko active Search and Examination
- 2021-06-24 WO PCT/JP2021/023905 patent/WO2021261544A1/ja active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN116034105A (zh) | 2023-04-28 |
| EP4174061A1 (en) | 2023-05-03 |
| CA3182966A1 (en) | 2021-12-30 |
| EP4174061A4 (en) | 2024-07-24 |
| JP7398159B2 (ja) | 2023-12-14 |
| BR112022026403A2 (pt) | 2023-05-02 |
| IL298559A (en) | 2023-01-01 |
| AU2021296087B2 (en) | 2023-08-17 |
| MX2022014760A (es) | 2023-01-11 |
| US20230183220A1 (en) | 2023-06-15 |
| WO2021261544A1 (ja) | 2021-12-30 |
| TW202216695A (zh) | 2022-05-01 |
| JPWO2021261544A1 (es) | 2021-12-30 |
| KR20230025007A (ko) | 2023-02-21 |
| AU2021296087A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
| PE20210477A1 (es) | Derivado policiclico de carbamoilpiridona | |
| AR106778A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo | |
| AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR111682A1 (es) | Derivados de imidazopirimidina con sustituyentes fenilo y piridilo que contienen azufre | |
| AR120982A1 (es) | Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre | |
| AR119971A1 (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| AR101798A1 (es) | Quinolinas herbicidas | |
| AR111672A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| AR120946A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| AR097795A1 (es) | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a | |
| AR118557A1 (es) | Quelantes de hierro derivados del ácido 4-(2,4-bis(2-hidroxifenil)-1h-imidazol-1-il)benzoico | |
| AR124222A1 (es) | Derivados heterocíclicos condensados | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
| AR122336A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| AR122711A1 (es) | COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA | |
| UA112109C2 (uk) | Сульфонамідні похідні бензиламіну для лікування захворювань центральної нервової системи (цнс) |